Selected Grants
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants Wi
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2025 - 2030External Relationships
- DocDelta Inc
- MJH Life Sciences
- MedTrend Intl LLC
- WorldOne Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.